Preventing Blood Clots
Thursday, December 10th, 2009Visit http://Bayer.VTENews.ca for more information.
Toronto, Ontario – September 16, 2008 Today, Canada became the first country to approve Xarelto® (rivaroxaban), the first in a new class of anticoagulants, for the prevention of venous thromboembolic events (VTE), or blood clots, in patients who have undergone elective total hip or total knee replacement surgery. As a [...]